The event will take place at the Company's headquarters in
Ovid management will provide updates on Ovid's scientific strategy and anticipated clinical development plans. Additionally, the Company's research and development leadership will review new data characterizing how the unique mechanisms of action in its pipeline address the underlying causes of neuronal hyperexcitability and may hold broader therapeutic potential in other central nervous system disorders. Also presenting will be recognized clinicians and academic thought leaders in epilepsy and rare neurological disorders, including:
In-person attendance is by invitation only. Those who would like to attend should contact
A live webcast of the presentation can be accessed through the Events and Presentations section of the Company's website at https://investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation.
About
Forward-Looking Statements
This press release includes certain disclosures that contain 'forward-looking statements,' including, without limitation: statements regarding the potential use of OV329, GV101 and OV350; the potential development of OV329, GV101 and the library of ROCK2 inhibitors and OV350 and other KCC2 compounds in Ovid's library; the potential therapeutic opportunity of OV329, GV101 and other ROCK2 inhibitors and OV350 and other KCC2 inhibitors; the potential opportunity for soticlestat and the timing of Takeda's two pivotal Phase 3 trials evaluating soticlestat for Dravet syndrome and Lennox-Gastaut syndrome. You can identify forward-looking statements because they contain words such as 'anticipates,' 'believes,' 'expected,' 'intends,' 'may,' 'plan,' 'potentially,' 'seek,' 'strive,' and 'will,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid's current expectations and assumptions. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, or risks related to Ovid's ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption 'Risk Factors' in Ovid's Quarterly Report on Form 10-Q filed with the
Contact:
Tel: 212-596-7231
Email: ovid@argotpartners.com
(C) 2023 Electronic News Publishing, source